Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Myriad Genetics launched Prolaris + AI, the first prostate cancer biomarker test to combine clinical-pathological features, molecular scoring, and AI-powered digital pathology. The test leverages technology from PATHOMIQ AI to help clinicians identify patients safe for active surveillance and personalize surveillance intensity, addressing a gap in traditional pathology tools. Validation studies showed the AI metric is a statistically significant predictor of Gleason upgrade at follow-up biopsy, independent of other clinical variables. The new metric is available for U.S.
Key figures
- Ai training cohort size
- 998
- Ai validation cohort size
- 296
- Projected us prostate cancer diagnoses
- 300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.